Navigation Links
Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
Date:6/24/2011

GENEVA, June 24, 2011 /PRNewswire/ -- Selexis SA is a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs. The Company announced today it will be showcasing the new Selexis SUREvariant Screening™ Service by giving away one free SUREvariant Screening at the 2011 BIO International Convention being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.  

Using the Selexis SUREvariant Screening Platform, Selexis will generate high-performance Selexis SUREpools™ for up to 4 monoclonal antibodies or recombinant protein variants, each SUREpool expressing a unique protein of interest.  Selexis will then transfer cell culture supernatants (Selexis SUREnatants™) from each of the Selexis SUREpools to contest winner for use in preclinical testing.

Contestants may enter the contest by dropping off a business card at the Selexis booth 1906 during exhibit hall hours.  There is no purchase necessary to enter the content.  Limit one entry per company.  The winner will be chosen by random ballot on the last day of the conference, Thursday, June 30, 2011.  

As described by industry thought leaders in recent technical conferences, producing preclinical lead proteins in a cGMP production platform can significantly improve preclinical decisions by reducing or eliminating heterogeneity of recombinant protein batches. The heterogeneity is caused by multiple technologies used in protein expression and impact mainly post-translational modifications.

Contest Description:

  • Rapid development of up to four (4) Selexis SUREpools, each expressing a monoclonal antibody or recombi
    '/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Verizon to Invest $125,000 to Support Domestic Violence Outreach, Prevention, Education and Awareness Programs in Virginia
7. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
8. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
9. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
10. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
11. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences announced ... research and development agreement (CRADA) with Aratana Therapeutics ... development of TRB-N0224 for the treatment and control ... and cats.  Traverse Biosciences has also granted Aratana ... treatment and control of periodontal disease in companion ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... MA (PRWEB) May 04, 2015 ... for drug discovery and life science research, today ... , the latest version of its enterprise solution ... biopharma R&D enables more efficient discovery and development ... approach to integrate and address protein optimization and ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12
... GLASGOW, Scotland, Sept. 3 Leading neurosurgical ... in neurosurgical,diagnostic and treatment devices, along with ... and efficient at the European,Association of Neurosurgical ... than 1,000 neurosurgeons and related medical professionals,will ...
... PARIS, September 2 Sanofi-aventis announced,today that ... 25 and STEEPLE,studies confirm clear net clinical ... infarction (STEMI) for Lovenox(R) vs,Unfractionnated Heparin (UFH). ... year results were presented during,hotline sessions at ...
... Standards and Technology (NIST) have developed two ... validate the performance of analytic instruments that ... Recent years have seen a significant increase ... analytic techniques. Researchers can detect, measure and ...
Cached Biology Technology:Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2
... L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental ... 3 minutes after turn-on. ... ... ...
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
APG5 autophagy 5-like (S. cerevisiae)...
Biology Products: